Low- and high-dose of radioiodine for the ablation of thyroid remnant in patients with differentiated thyroid cancer coexisting Hahimoto thyroiditis: a prospective randomized trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027445

Enrollment

Unknown

Registered

2019-11-13

Start date

2019-12-23

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid cancer coexisting Hahimoto thyroiditis

Interventions

1:high-dose of radioiodine

2:low-dose of radioiodine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The pathologic diagnosis was papillary, follicular thyroid carcinoma (T1-3N0-1aM0)with hashimoto's thyroiditis.The patients were treated with iodine-131 for 1 to 6 months after total thyroidectomy.

Exclusion criteria

Exclusion criteria: Positive Tg antibody; Serious damage of liver and kidney function; Pregnant or lactating women; Myelosuppression (WBC < 3.0 x 10^9/L); Chest CT with malignant signs; Neck ultrasound showed malignant signs.

Design outcomes

Primary

Measure	Time frame
successful thyroid remnant ablation;	—

Secondary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactMa Chao

Department of Nuclear Medicine, the Tenth People's Hospital of Tongji University

ponymachao@163.com+86 18721288964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026